Form 4 for SUPN SUPERNUS PHARMACEUTICALS, INC.
Accepted 2024-11-12 00:00:00 ET · period of report 2024-11-08 · accession 0001628280-24-047145 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-11-12 | 2024-11-08 | SUPN | GEMAYEL GEORGES | Dir | M - OptEx | $11.46 | +10.8K | 24.1K | +81% | +$123.6K |
| D | 2024-11-12 | 2024-11-08 | SUPN | GEMAYEL GEORGES | Dir | S - Sale+OE | $36.30 | -10.8K | 13.3K | -45% | -$391.6K |
| D | 2024-11-12 | 2024-11-08 | SUPN | GEMAYEL GEORGES | Dir | M - OptEx | $0.00 | -10.8K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-11-08 | M | A | 10,787 | $11.46 | 24,102 | D | — | — | |
| 2 | Common | Common Stock | 2024-11-08 | S | D | 10,787 | $36.30 | 13,315 | D | — | — | (F1) The Reporting Person exercised the options indicated herein and sold the underlying shares prior to the expiration of such options on March 23, 2025. (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.01 to $36.57. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| 3 | Derivative | Director Stock Option (Right to Buy) | 2024-11-08 | M | D | 10,787 | $0.00 | 0 | D | $11.46 · 2016-03-23 to 2025-03-23 | 10,787 Common Stock |